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Signaling pathwayRecent studies have identiﬁed important roles formicroRNAs (miRNAs) inmany cardiac pathophysiological pro-
cesses, including the regulation of cardiomyocyte hypertrophy. However, the role of miR-350 in the cardiac set-
ting is still unclear. The objective of this study is to determine whether miR-350 alone can induce pathological
cardiac hypertrophy by repressing the SAPK pathway in cardiomyocytes. Here we report that miR-350 plays a
key role in determining pathological cardiomyocyte hypertrophy and apoptosis. Comprehensivemicroarray pro-
ﬁling of miRs and qPCR showed that this unique miRNA was signiﬁcantly up-regulated in rat hearts in response
to late-stage transverse aortic constriction. Western blotting and luciferase assays conﬁrmed that the target
mRNAs of miR-350 are mitogen activated protein kinase (MAPK) 11/14 and MAPK8/9 gene transcripts. Gain-
of-unction and loss-of-function approaches were used to investigate the functional roles of miR-350. The forced
over-expression of miR-350 was sufﬁcient to induce hypertrophy of cardiomyocytes through the posttransla-
tional suppression of p38 and JNK protein synthesis. Moreover, miR-350 led to an increase in unphosphorylated
NFATc3 and its nuclear translocation, resulting in the over-expression of pathological hypertrophy markers. As
predicted, these effects could effectively be imitated by siR-JNK/p38 through the degeneration of p38 and JNK
mRNAs. Conversely, antagomir-350 could lower the levels of miR-350, reverse the expression of target proteins
and reduce cell size and apoptosis relative to the administration of mutant antagomir-350. Our data provide the
ﬁrst evidence that miR-350 is a critical regulator of pathological cardiac hypertrophy and apoptosis in rats.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Epidemiological studies have shown that cardiac hypertrophy (CH)
induced by sustained pressure-overload is a major risk factor for ische-
mic heart disease, arrhythmia, and sudden death [1,2]. Mitogen-
activated protein kinases (MAPKs), including the extracellularly re-
sponsive kinases (ERKs), the stress-activated protein kinases (SAPKs)
such as the c-Jun N-terminal kinases (JNKs), and the p38 MAPKs, have
been found to play an important role in CH [3–5]. Although it has
been shown that constitutive activation of the ERK 1/2 pathway signif-
icantly induces cardiac enlargement, the respective roles of the JNK andCAS, 15 Datun Road, Chaoyang
fax: +86 10 64888572.
yin@sun5.ibp.ac.cn,
rights reserved.p38 pathways are controversial [3,4,6–10], suggesting that additional
regulatory mechanisms remain to be identiﬁed.
MicroRNAs (miRNAs) are a class of short, noncoding RNAs of 22nt
that serve as important regulators of gene expression [11]. They nega-
tively regulate target gene expression through base paring to the 3′
untranslated region (UTR) of target mRNAs, which leads to translation
repression and/or mRNA cleavage [11,12]. miRNAs have been shown
to affect stem cell differentiation, organ development, apoptosis, signal-
ing pathways, disease and cancer, and respond to biotic and abiotic
environmental stresses [12,13]. Moreover, several studies have demon-
strated that expression of somemiRNAs displays unique tissue-speciﬁc,
development-speciﬁc or etiology-speciﬁc patterns [11,14,15]. Recently,
studies have identiﬁed expression patterns of microRNAs associated
with cardiovascular diseases. For example, miRNA-21, miR-23a, miR-
24, miR-133, mIR-208/miR-195 and miR-199 are involved in CH [16–
18], miRNA-1 in arrhythmia [19], miRNA-29 and−21 in cardiacﬁbrosis
[20,21], miR-210 and −494 in ischemic heart disease [22,23] and
miRNA-129 in heart failure [24]. However, it is not known how or
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pathological CH and heart failure at later stages.
To address the role of JNK and p38 pathways in the response of the
heart to stress and the molecular regulation of miRNA on the SAPK
pathway in CH, we analyzed the expression proﬁle of miRNAs in
pressure-overload-induced CH. Our results show that miR-350 can
be induced by mechanical stimuli, and convey the hypertrophic signal
by repressing the translation of JNK1/2 and p38. MiR-350 may be a
useful marker to indicate the transition from an adaptive response
to maladaptive heart failure, and a promising target for treating CH.
2. Methods
2.1. Cell culture and transfection
Heart-derived H9c2 cardiomyoblasts were obtained from the
American Tissue Culture Collection (ATCC). H9c2 cells were cultured
with Dulbecco's modiﬁed Eagle's medium (DMEM) supplemented
with 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM glutamine,
1 mMHEPES buffer, and 10% fetal bovine serum (Clontech) in humid-
iﬁed air (5% CO2) at 37 °C. The day before transfection, the cells were
trypsinized, diluted with fresh mediumwithout antibiotics, and seed-
ed into 6-well culture plates (approximately 106 cells/well). shR-p38/
JNK or miR-350 vectors were synthesized by Shanghai GenePharma
(Shanghai, China). The sequences of shR-p38/JNK, miR-350 and mu-
tant miR-350 (miR-350 m) are:
shR-p38/JNK gene,
TGA AGATTCTTG ATTTTCGTTCAAGAGACCAAAATCAAGAATCTTCA;
Wild type miR-350 gene,
GTGAAAGTGTATGGGCTTTGGGAATTCAAGAGATTCACAAAGCCCATAC
ACTTTCAC;
Mutant miR-350 gene,
GGGACAGTGTATGTGCTAAGCCTATTCAAGAGATACGCTTAGCACAT
ACACTGTCCC.
The vector expressing GFP alone or mutant miR-350 was used as a
control. Vectors were transfected using the Fugene transfection reagent
(Roche, USA) according to the manufacturer's instructions.
2.2. Microarray
Total RNA was extracted from rat cardiomyocytes that had under-
gone transverse aortic constriction (TAC) or shamoperation, using TRIzol
reagent according to the manufacturer's protocol (Invitrogen). The
miRCURY™ locked nucleic acid (LNA) arrays (Exiqon, Vedbaek, Den-
mark) consist of 1300 capture probes for rat and mouse and human.
Twenty micrograms of RNA were sent to KangChen Bio-tech (Shanghai,
China) for microRNA microarray analysis. Samples were enriched for
small RNAs, after which each pair of sham and TAC samples was labeled
with Cys3 andCys5ﬂuorescent dyes andhybridized to amiRCURY™ chip
that held all of the 1300 mature microRNA probes identiﬁed to date, as
well as perfectly matched and mismatched probes for quality control.
Data were normalized in two separate steps for each microarray as de-
scribed previously [25].
2.3. Real-time TaqMan PCR analysis on the expression of miR-350
Total RNA was isolated using TRIzol reagent (Invitrogen) according
to the manufacturer's instructions. Reverse transcriptase reactions
were performed with 1 μg of puriﬁed total RNA, 50 nM stem-loop RT
primer (Applied Biosystems), 1× RT Buffer, 0.25 mM of each dNTP,
5 U/μl M-MLV reverse transcriptase (Promega) and 0.25 U/μl RNase in-
hibitor (Promega). The reactions were incubated in a thermocycler for
30 min at 16 °C, 30 min at 42 °C, 10 min at 85 °C and then held at
4 °C. All reverse transcriptase reactions, including controls, were run
in duplicate. Real-time PCR was performed using a standard TaqMan
MicroRNA Assay protocol on a Roter-Gene 6000 (Corbett) SequenceDetection System [26]. The 20 μl PCR reactions included 1 μl RT product,
1× Real-time PCRMasterMix including TaqMan probe, 0.15 μMmiRNA
speciﬁc primer set. The reactions were incubated at 95 °C for 3 min,
followed by 40 cycles of 95 °C for 15 s and 60 °C for 40 s. All reactions
were run in triplicate. The TaqManCT valuewas converted into absolute
copy numbers using a standard curve from a synthetic miRNA standard.
2.4. Antagomir experiments
Single-stranded RNAs were synthesized by GenePharma Co. Ltd.
Chemically modiﬁed antagomir complementary to miR-350 was used
to inhibit expression. The sequence used was 5′-GUGAAAGUGUAUGG
GCUUUGUGAA-3′ (miR-350-anti). A chemically modiﬁed mutant se-
quence 5′-GUCAAUGUGAUAGCGCUCACGUAA-3′was used as a negative
control (miR-350-NC). Underlined letters aremutated nucleotides. All of
the bases were 2′-OMe modiﬁed. The transfection of antagomir or
antagomir-NCwas performedusingGenofectin™ (Geno Biotech Beijiing,
http://www.geno-bio.cn) [26].
2.5. Luciferase assays
pRL-TK vectors (Promega), with orwithout a target sequence such as
MAPK11/14 or MAPK8/9, were cotransfected with miRNA-350 or mu-
tantmiRNA-350 vectors. Cellswere harvested and lysed 24 h after trans-
fection, and Renilla luciferase activities were measured consecutively
using dual luciferase assays (Promega), according to the manufacturer's
instructions, using a Berthold Lumat 4097 Luminometer (Perkin Elmer
Life Sciences, Carlsbad, CA).
2.6. Immunoﬂuorescence
Cells grown in 24 well plates and subjected to various treatments
were subsequently washed three times with cold PBS, and then ﬁxed
with 4% paraformaldehyde at room temperature for 30 min. After ﬁxa-
tion, cells were washed three times with cold PBS and permeabilized
with 0.5% Triton X-100 for 10 min at 4 °C. Non-speciﬁc binding of the
ﬁxed cells was blocked with PBS containing 2% bovine serum albumin
at 37 °C for 30 min, followed by incubation with primary NFATc3 anti-
body (Santa Cruz, CA) overnight at 4 °C. After washing, the cells were
incubated with Alexa Fluor 568-conjugated anti-goat antibody at
37 °C for 1 h; cells were stained with Alexa Fluor 568-conjugated anti-
body alone as a negative control. Actin ﬁlaments were visualized using
rhodamine-labeled phalloidin. The cells were examined and photo-
graphed using a ﬂuorescence microscope coupled to an image analysis
system. Surface areawas quantiﬁed by imaging to the boundary of indi-
vidual cells under various conditions using computer assisted image
analysis (Adobe Photoshop 5.0; Adobe, NIH Image J). Approximately
30–40 cells for each condition were counted and regarded as an inde-
pendent experiment; three independent experiments were performed
for each condition.
DAPI stainingwas used to visualize the nucleus. Cells grown in 24well
plates were divided into several groups for various treatments. After
treatments, cells were ﬁxed with 4% paraformaldehyde solution for
30 min at room temperature. After a rinse with PBS, the samples were
incubated with 1 mg/ml 4-6-diamidine-2-phenylindole dihydrochloride
(DAPI, Roche) for 30 min to enable the cell nucleus to be visualized
(blue stains) by UV microscopy.
2.7. MTT assay
A total of 8×103 cells were seeded into each well of a 96-well plate
andallowed to adhere for 18 h. The cellswere then transfectedwith var-
ious vectors. At day 1, 3, 5, and 7 after the transfection, cell viability was
analyzed using a 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium
bromide (MTT, Sigma) assay. The optical density was measured using a
microculture plate reader (Bio-Rad 3550) at 540 nm. Absorbance values
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the percentage cell survival.
2.8. Flow cytometry
Cultured cells were treated with various vectors or regents. At day 2
after transfection, apoptotic cells were detected using Annexin V-PE and
propidium iodide (PI) double labeling. The procedure was performed
according to the manufacturer's instructions. Flow cytometry (Becton
Dikinson, USA) was used to assess the number of apoptotic cells.
2.9. Western blotting
Protein was prepared from cultured cells as previously described.
Brieﬂy, pre-stained molecular-weight markers and 50 μg cytosolic pro-
tein were separated on a 10% SDS-PAGE gel. Separated proteins were
electrophoretically transferred to a 0.45-μm polyvinylidene diﬂuoride
membrane. The membrane was blocked overnight at 4 °C in PBS con-
taining 5% nonfat milk, then probed with speciﬁc primary antibodies:
phospho-MAPK14 (Cell Signaling Technology, Inc.), phospho-JNK1
(Cell Signaling Technology, Inc.), unphosphorylated NFATc3 (Santa
Cruz Biotechnology, Inc.), beta-actin andGAPDH (Cell Signaling Technol-
ogy). Horseradish peroxidase-labeled anti-rabbit IgG, diluted 1∶3000 in
PBS, were used as the secondary antibody. Speciﬁc protein bands were
visualized using an enhanced chemiluminescence system (Amersham)
according to the manufacturer's instructions. Band densities fromWest-
ern blots were quantiﬁed using Adobe Photoshop CS4 Extended version
11.0.2 (Adobe, USA). The normalized intensity of eachband is the ratio of
control (actin)/background-corrected raw intensities of protein of inter-
est .
2.10. Quantitative real-time PCR
Total RNAwas extracted from snap-frozen heart using TRIzol reagent
(Invitrogen). The yield and purity of the RNA were determined spectro-
photometrically using the A260/A280 ratio. Onemicrogram of RNA was
reverse transcribed into cDNA using the SuperScript ﬁrst-strand synthe-
sis system (Applied Biosystems). cDNA (25 ng) was subjected to PCR
ampliﬁcation using the TaqMan RT-PCR Master Mix reagent (Applied
Biosystems). TaqMan primers and probes for alpha-actin, beta-myosin
heavy chain, atrial natriuretic peptide (ANP) and (BNP) and GAPDH
were purchased from Applied Biosystems. The sequences of primers
were listed in Table 1.
2.11. Transgenic mice
The linearized gene vectors (pGPU6/GFP/Neo) expressing miR-350
or miR-350 m were injected into fertilized eggs of C57BL/6J mice
using a TE2000-U micro‐injection instrument. Thirty ICR mice were
employed as sham pregnant receptors for the preparation of transgenic
mice. All experimental procedures involving animals were approved byTable 1
Primers for RT-PCR.
Gene Sense(5′→3′) Antisense(5′→3′)
β-actin TGCTGATGGACTCCGGTGAC CGCCAGACAGCACTGTGTTG
GAPDH GAAGGTGAAGGTCGGAGTC GAAGATGGTGATGGGATTTC
ANP ATCTGATGGATTTCAAGAACC CTCTGAGACGGGTTGACTTC
BNP ACAATCCACGATGCAGAAGCT GGGCCTTGGTCCTTTGAGA
a-MyHC AACGCCCAAGCCCACT TGAA CATT GGCA CGGACTGC GTCA
beta-MyHC GAGCCTCCAGAGTTTGCTGAAGGA TTGG CACGGACT GCGTCATC
p38 CCGAACAAAGGGAGAACCG TGGACTGCATACTGAGGCG
JNK AAGACAGGGGAGCAGACG GGTGGCAAGAAGGTGGAG
ERK1/2 CCTAACAAGAACAGACACCC CAATCACCCACACACAGAAG
BCL-2 ATGCCAAGGGGGAAACAC CGACGGTAGCGACGAGAG
NFATc3 AAGACAGGGGAGCAGACG GGTGGCAAGAAGGTGGAGthe Animal Welfare and Management Committee of Experimental
Institute of Zoology, Chinese Academy of Medical Science (Approval
number: GC-09-2078).
2.12. Statistical analysis
All values are expressed as mean±SD. Student's t-test was used for
two-group comparisons. Comparisons of parameters among three or
more groups were analyzed by 1-way ANOVA for single factor or 2-way
ANOVA for two-factor variables with repeated measures, followed by
Student's t-test with Bonferroni's correction for multiple-comparisons.
Differences were considered statistically signiﬁcant at a value of Pb0.05.
3. Results
3.1. TAC rats
To investigate whether and which miRNAs are involved in patholog-
ical late stage CH, we induced CH by TAC and compared miRNA expres-
sion proﬁles between different cases. Fig. 1A shows that TAC induced a
remarkable enlargement in heart size compared with a sham operation
(Fig. 1A and B,Table 2 and Suppl. Fig. 1). The heart-to-body weight ratio
averaged 1.5-fold greater in the TAC cases than in control littermates at
week 7 post-surgery (Table 3). Histological analysis demonstrated CH
wherein the diameter of the ventricular cardiomyocytes was signiﬁcant-
ly larger in TAC than in sham (Fig. 1C and Suppl. Fig. 2). In contrast to
the well-organized, striated musculature of the normal ventricular
wall, cardiomyocytes of TAC hearts were disorganized and obviously hy-
pertrophic (Fig. 1C). In the early stage (4 weeks after treatment), TAC
treatment showed a slight hypertrophic effect on LVPWTd and LVEDd
without the features of heart failure present in the operated group
(Table 2). By 7 weeks of age, however, all the animals treated with
TAC showed a signiﬁcant increase in LVPWTd, LVEDd and heart-to-
body weight ratios. More importantly, these operated rats developed di-
lated cardiomyopathy with aging and exhibited heart failure in contrast
to wild type (WT) and sham rats at later stages (Table 2).
3.2. Cardiac pressure overload induces the expression of miR-350
On the basis of the successful establishment of the TAC rat model
with pathological CH, we employed miRNA chips to test the alteration
in the expression proﬁles of miRNAs in the cardiomyocytes of operated
and sham-operated rats. Of the 1300 individual miRNAs represented on
themiRCURY™, 144 showed a decrease of more than 1.5-fold in the re-
mote myocardium, whereas only one displayed an increase of more
than 2-fold in expression (Fig. 1D and Suppl. Tables 1). The array data
were conﬁrmed by real-time PCR analysis usingmiRNA-speciﬁc probes.
miR-350 expression within cardiomyocytes was at least eight times
higher in TAC-treated than in sham-operated cases. However, miR-350
expression was not different between TAC-treated and sham-operated
rats in the early stage (Fig. 1E). In contrast to the observation that 27
miRNAs showed increased expression in mouse hearts subjected to
TAC intervention for 3 weeks [18,27], this highly upregulated miR-350
within cardiomyocytes was detected only in the late stage of pressure
overload-induced hypertrophy (Fig. 1E), suggesting that the expression
patterns of miRNAs in CH are different in the early and late stages.
3.3. miR-350 alone can inhibit both JNK and p38 pathways at the same
time
To identify potential target genes of miR-350, we used our own bio-
informatics tool [28] andmiRanda to predict putative targets formiRNAs.
Among the predicted target genes for miR-350 (Suppl. Table 2), six SAPK
members - MAPKK3/7, p38-α (MAPK14), -β (MAPK11) and MAPK8/9
(JNK1/2) - were identiﬁed. P38 and JNK were selected for further valida-
tion because they are phylogenetically conserved and contain more than
Fig. 1. Overexpression ofmiR-350 in pressure overload‐induced cardiac hypertrophy. (A) Sham rats and banded ratswere killed at 7 weeks after operation, and the hearts were removed.
(B) RepresentativeM-mode echocardiographic images in TAC and sham-operated rats. (C) Highmagniﬁcation views of left ventricularwalls of hearts from shamand banded rats, respec-
tively. Vertical sections through hearts of shamand banded rats at 7 weeks of age stainedwithH and E. (D)Microarray analysis on expression proﬁles of themiRNAs in the left ventricular
myocardium from the sham-operated (red) and TAC-treated (blue) rats. Most miRNAs were down-regulated during cardiac hypertrophy whereas only miR-350 was signiﬁcantly
up-regulated (Insert). (E) Differential expression of miR-350 detected by qRT-PCR assay in sham and banded hearts. Data are averages of three independent determinations. Error
bars indicate standard deviations. ⁎Pb0.001, TAC compared with the sham group.
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gion (UTR) (Fig. 2A). Interestingly, MAPKK4, p38 and JNK have been
found to exert critical effects on pathological CH [3,10,29,30].
To determine whether miR-350 over-expression leads to the sup-
pression of both p38 and JNK genes, we transfected a rat embryonic ven-
tricular myocardial cell line (H9c2) with vectors expressing miR-350
and green ﬂuorescence protein (GFP) transgenes. As shown in Fig. 2B,
the levels of miR-350 were signiﬁcantly higher following transfection
withmiR-350 vectors thanwith control vector, shR-p38/JNK vector,mu-
tant miR-350 vector (miR-350 m), angiotensin II (Ang II) or ﬁbroblast
case. Subsequently, the luciferase activity assay was used to validate
the efﬁcacy of miRNA-350, using a luciferase reporter bearing different
target sequences including MAPK11/14 (p38) or MAPK8/9 (JNK1/2)
cloned into its 3′-UTR. Quantitative experiments revealed that miRNA-
350 resulted in a signiﬁcant decrease in luciferase expression (by 45–
60%), while the mutant miRNA-350 caused no measurable reduction
(Fig. 2C). This observation was further supported by the Western blot-
ting data, which showed that increased levels of miR-350 caused aTable 2
Effects of aortic banding on the left ventricular geometries and EF.
Group n Time IVSTd (mm)
Control 5 4 weeks 1.63±0.21
5 7 weeks 1.87±0.21
Sham 5 4 weeks 1.73±0.16
5 7 weeks 1.83±0.12
AB 10 4 weeks 2.34±0.11⁎
10 7 weeks 2.40±0.03⁎
Values are means±SEM. AB: aortic banding; LVEDd: Left ventricular end-diastolic dimension; LV
end-diastolic thickness; EF: ejection fraction.
⁎ Pb0.05 and;
⁎⁎ Pb0.01 vs. sham.signiﬁcant decrease in p38 and JNK1/2 phospho-proteins (Fig. 2E). In
contrast, PCR analysis indicated that there were no detectable changes
in the levels of phospho-p38 and phospho-JNK1/2 mRNAs, indicating
that miR-350 modulates p38 and JNK expression by repressing transla-
tion (Fig. 2D). Conversely, when 100 nM Ang II was added to the medi-
um, therewas a signiﬁcant increase in the levels of phospho-JNK1/2 and
phospho-p38 MAPK and a decrease in unphosphorylated NFATc3; the
cells from the control andmiR-350 m cases showed no or slight changes
at themRNA and protein levels of both p38 and JNK(Fig. 2E). Further ex-
periments have demonstrated that, in the cells treated with shR-JNK/
p38, both JNK/p38 mRNAs and proteins were down-regulated. These
data strongly support the suggestion that p38 and JNK are direct targets
of miR-350 (Fig. 2E and F).
3.4. miR-350 can induce cardiomyocyte hypertrophy
To clarify whether the increased expression of miR-350 is a cause or
simply a consequence of CH, we ﬁrst treated H9c2 cells with miR-350LVPWTd (mm) LVEDd (mm) EF
1.73±0.12 4.74±0.13 90.72±5.87%
1.77±0.17 4.50±0.19 88.93±4.57%
1.75±0.13 4.83±0.28 89.36±5.11%
1.76±0.47 4.90±0.06 92.06±5.58%
1.84±0.25 4.91±0.48 88.34±5.37%
2.52±0.24⁎⁎ 6.83±0.28⁎⁎ 68.34±4.27%⁎⁎
PWTd: Left ventricular posterior wall end-diastolic thickness; IVSTd: Interventricular septal
Table 3
Effects of aortic banding on heart mass and body weight.
Group Rat number HW(g) LVM(g) HW/BW(g/kg) LVW/BW(g/kg)
Control 5 0.99±0.15 0.71±0.11 2.88±0.46 2.04±0.23
Sham 5 0.93±0.16 0.74±0.08 2.98±0.26 2.18±0.28
LVH 10 1.24±0.15 0.97±0.07 4.34±0.39⁎ 3.40±0.11⁎
BW, bodyweight; LVM, left ventriclemass; HW, heart weight; LVW, left ventricle weight ;
LVH, left ventricular hypertrophied group. Data are mean±standard error (SE).
⁎ Pb0.05 vs. Control.
5Y. Ge et al. / Biochimica et Biophysica Acta 1832 (2013) 1–10vectors and then subjected them to actin-immunoﬂuorescence analysis
to observe actin ﬁber formation and measure the cellular area. After
transfection with vectors for varying lengths of time (1, 3, 5 and
7 days), we observed a notable change in cell morphology. Following
transfection with miR-350 vectors, H9c2 cells exhibiting a green ﬂuo-
rescence changed their shapes over time: they initially had a short
spindle, which changed ﬁrst to a long spindle, then to a wide one,
and ﬁnally to polymorphy (Fig. 3A), displaying a marked increase in
the organization of the actin ﬁlaments (Fig. 3B). Quantitative analysis
showed that the area of the individual H9c2 cell signiﬁcantly increased
by approximately 1.4 fold at day 3, 1.8 fold at day 5 and 2.3 fold at day 7
compared with cells treated with control or mutant vectors (Fig. 3C
and Supplementary Fig. 4). Administration of miR-350 antagomir led
to a reduction in miR-350 levels and abolished miR-350-induced
H9c2 hypertrophy (Fig. 3B and C). This ﬁnding suggests that adminis-
tration of miR-350 vectors dramatically induces myocardial cell hyper-
trophy by repressing both p38 and JNK1/2, and that miR-350 plays a
direct role in inducing cardiomyocyte hypertrophy.
Consistent with the observation that there is an increase in apo-
ptotic myocytes with CH and heart failure in the aortic-banded rat,
obvious morphological changes were observed in H9c2 cells, with
cell shrinkage (the morphological hallmark of apoptosis) following
the transfection with miR-350 vectors. Correspondingly, the MTT
assay showed a time-dependent decline in cell viability at time inter-
vals from 1 to 5 days following treatment with miR-350 vectors and
shR-JNK/p38 (Fig. 3D). Administration of miR-350 antagomir attenu-
ated miR-350-induced cardiomyocyte death. To clarify whether miR-
350-induced cell death was due to apoptosis, we performed ﬂow cy-
tometry analysis of Annexin V/PI-stained cells (Fig. 3E and F).
According to the FACS analysis, apoptosis of transfected H9c2 cells
could be detected at 48 h following transfection and continued from
that point forward. It suggests that the cardiomyocyte death caused
by miR-350 may make an important contribution to dilated cardio-
myopathy and heart failure at late stage.
3.5. shR-JNK/p38 is able to imitate miR-350 in inducing hypertrophy
If an increase in miR-350 level is required for pathological hypertro-
phy of myocardial cells (MCs), then direct inhibition of its target genes,
jnk and p38, should have similar effects on those cells. Therefore, we
next studied whether over-expression of shR-JNK/p38 with the ability
to knockdown both JNK1 and p38 mRNA targets in cultured H9c2 cells
canmimicmiR-350-induced CH. Quantitative RT-PCR analysis illustrated
that shR-JNK/p38 greatly repressed endogenous p38 expression, com-
pared with control and miR-350 m transfected cells (Fig. 2D). As
expected, MCs treated with shR-JNK/p38 vectors were indeed induced
to hypertrophy, as determined by the measurement of cell size (Fig. 3),
whereas control vectors showed no effects on the enlargement of MCs.
However, the alteration in the size of cardiomyocytes caused by shR-
JNK/p38was less than that observed in themiR-350-treated cells. There-
fore, the over-expression of naturalmiR-350may bemore effective in in-
ducing the enlargement of cardiomyocytes than artiﬁcial knockout of
p38 and JNK1/2, suggesting that complete inhibition of the p38 and
JNKpathways is essential for pathogenic hypertrophy of cardiomyocytes.
Taken together, our ﬁndings provide direct evidence that miR-350 dic-
tates the enlargement of cardiomyocytes via repression of the p38 andJNK pathways, suggesting that the activation of miR-350 may be signiﬁ-
cantly associated with massive cardiac enlargement.
3.6. miR-350 causes an increase in the level of unphosphorylated NFATc3
proteins and dramatic up-regulation of the hypertrophic markers
We next examined the translocation of unphosphorylated NFATc3
from the cytoplasm to the nucleus in response to administration of the
miR-350 vector. As shown in Fig. 4, H9c2 cells were treated with miR-
350 vectors (3 μg/ml) for 3 days, then assayed by immunoﬂuorescence.
The presence of themiR-350 vector induced a signiﬁcant increase in the
unphosphorylated NFATc3 proteins (Fig. 2E and F) and their transloca-
tion to the nucleus (Fig. 4A and B). We also examined the distribution
of NFATc3 in both the cytoplasm and nucleus following treatment
with different agents (Fig. 4B). We observed that the nuclear level of
NFATc3 was dramatically increased following miR-350 vector (3 μg/ml)
treatment, accompanied by a relative reduction in the cytosolic level of
NFATc3. Similarly, shR-JNK/p38 induced the same response. In contrast,
the presence of Ang II, mutant miR-350 vectors or miR-350 antagomir
did not lead to a redistribution of NFATc3 from the cytoplasm to the
nucleus (Fig. 4B). These results suggest that the miR-350 suppression of
p38 and JNK leads to an increase in unphosphorylated NFATc3 and to
its nuclear translocation.
To understand whether the expression of genes associated with
myocardial pathological hypertrophy was induced by miR-350 vec-
tors, cultured H9c2 cells were treated with various agents for 48 h,
and then subjected to real-time PCR analysis. The results showed a
dramatic up-regulation of the hypertrophic markers atrial natriuretic
peptide (ANP), B-type natriuretic peptide (BNP), beta-myosin heavy
chain (β-MHC), and skeletal alpha actin (SKA) in response to cardiac
over-expression of miR-350 (Fig. 4C). These results suggest that the
miR-350 suppression of p38 and JNK results in marked increases in
the mRNA levels of the pathological hypertrophy markers ANP, BNP,
b-MHC and SKA, implying that the induction/regulation of their ex-
pression is mediated by NFATc3 (Fig. 4D).
3.7. Loss-of-function assay proves the hypertrophic roles of miR-350
The next question to be investigatedwaswhether blockingmiR-350
expression in cardiomyocytes could prevent hypertrophy. To test this
idea, we performed in vitro studies in which an antagomir speciﬁc for
miR-350 (miR-350-anti) or a mutant antagomir (miR-350-NC), and
miR-350 vector were co-transfected into cells. When cells were treated
with miR-350-anti, miR-350 activity was signiﬁcantly repressed
(Fig. 2B). As shown by PCR analysis and Western blotting (Fig. 2G and
H), neither p38 and JNK genes nor proteins showed alternation. Quan-
titative analysis of cell size revealed thatmiR-350-anti treatment signif-
icantly attenuated the hypertrophy provoked by miR-350 (Fig. 3B and
C). MTT analysis indicated that miR-350-anti effectively prevented the
cell death mediated by miR-350 (Fig. 3D). Similarly, immunochemical
staining illustrated that NFATc3 translocation could be blocked by this
antagomir (Fig. 4B). However, treatment of H9c2 cells with both miR-
350-NC and miR-350 vectors had no effect on the expression level of
miR-350 comparedwith the control (Fig. 2B). In parallel, administration
of antagomir-350, but not the antagomir-350 mutant, was associated
with signiﬁcantly increased levels of JNK and p38 protein in the cells
(Fig. 2H). Furthermore, we observed that the relative area of cells was
signiﬁcantly reversed in the antagomir-350‐treated cells (1396±120
versus 1258±86) compared to the control (Pb0.05; Fig. 3B and C).
Apoptosis of H9c2 cells, NFATc3 translocation and expression of fetal
genes did not differ signiﬁcantly among the control, mutant and
miR-350-anti groups (Figs. 3D and 4). Taken together, these results sug-
gest that administration of inhibitory miR-350 molecules (i.e., miR-
350-anti) may protect these cardiomyocytes from pathological hyper-
trophy [31,32].
Fig. 2. The ectopic expression ofmiR-350 caneffectively inhibit the expression of endogenous p38 and JNK genes at the translational level. (A) Sequence alignment of the rat p38 and JNK3′UTRs
and mature miR-350. Base-pairing between miR-350 seed sequences with MAPKs 3′ UTR is marked in red. (B) Differential expression of miR-350 in various cases. Cultured cardiocytes were
treated with Ang II (100nM) or different vectors for 48 h. Small RNA was isolated and detected by real-time PCR. Data are averages of at least three independent determinations. Error bars
indicate standard deviations. ⁎Pb0.001 and ⁎⁎Pb0.01; miRNA-350 compared with the control group and miR-350+anti, respectively. #p>0.05; miRNA-350 compared with miR-350+NC.
(C) The miRNA-350 or mutant miR-350 vector [2 μg] together with 2 μg pRL-TK reporter plasmids with or without a target sequence of the miRNA-350 were cotransfected into cardiocytes,
and 24 h after transfection a dual luciferase assay was carried out. Relative levels of the expressed luciferase activity under various conditions were determined and normalized to their levels
in the control. The data are the averages of at least three independent determinations. Error bars indicate standard deviations. ⁎Pb0.01;miRNA-350 comparedwith the control group. (D)Quan-
titative RT-PCR analysis of the expression levels of relatedmRNAs under various conditionswas carried out 48 h after treatment. Data are averages of at least three independent determinations.
Error bars indicate standard deviations. ⁎Pb0.005. (E) The levels of related proteins were analyzed byWestern blotting. TheWestern blot was stripped and re-probedwith β-actin antibody to
determine total protein loading. (n=3). (F) The quantitative analysis on the blottingwas performed. Error bars indicate standard deviations. ⁎Pb0.05; shR-JNK/p38 comparedwith the control
group. #Pb0.01;miRNA-350 or shR-JNK/p38 comparedwith the control group. (G) PCR analysis of the expression levels of relatedmRNAs under three different conditionswas carried out 48 h
after treatment. (H) The levels of phospho-p38 and phospho-JNK proteins were analyzed by Western blotting. The graph is a representative of three experiments.
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Fig. 3. The ectopic expression ofmiR-350 signiﬁcantly induces the enlargement of cardiomyocytes and cell apoptosis. (A)Morphological changes in H9c2myocardial cells in a time-dependent
manner. (B) H9c2 myocardial cells were treated without or with various agents and stained by actin-immunoﬂuorescence to reveal sarcomeres, and with Hoechst stain to reveal nuclei. Cells
were transfectedwithmutantmiR-350 vectors (miR-350 m) as a negative control or stimulatedwithAng II (100 nM), a potent inducer of hypertrophy, as a positive control. (C) The relative cell
size in response to various conditions at different time-points was analyzed. Data are means±SD of 160 cell measurements from three independent experiments. ⁎Pb0.001 and ⁎⁎Pb0.01;
miRNA-350 and shR-JNK/p38 compared with the control group, respectively. #p>0.01; miRNA-350 compared with miR-350+anti. (D) The effects of different agents on cell viability were
examined byMTT assay. Data aremeans±SD. ⁎Pb0.05 or ⁎⁎Pb0.01 comparedwith control at day 5. #p>0.05;miRNA-350+anti or AngII comparedwith control, respectively. (E) H9c2myo-
cardial cells were transfectedwithmiR-350, shR-p38 ormiR-350 m. Cells were sampled at 60 h, and apoptosis was determined via Annexin V-PE and PI co-staining. Data are representative of
three experiments. The corresponding quantitative analysis was shown in (F). #Pb0.05 and ⁎Pb0.01; miRNA-350 and shR-JNK/p38 compared with the control group, respectively.
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Fig. 4. Nuclear translocation of NFAT-3 and up-regulation of pathological hypertrophy markers in miR-350-treated myocardial cells. (A) Cultured cardiomyocytes were either untransfected,
stimulatedwithAng II, or transfectedwithmiR-350-, shR-p38-, ormiR-350 m-vectors for 60 hand immunostained for subcellular locationofNFATc3. In the control, Ang II andmutationgroups,
NFATc3wasnot induced to translocate to the nucleus, as distinct from the effect ofmiR-350 and shR-p38 vectors. These resultswere observed in three independent experiments. (B) The results
shown in (A)were quantiﬁed. Data shown aremeans±SD of 120 cell measurements from three independent experiments. ⁎Pb0.001 and ⁎⁎Pb0.01 comparedwith control. (C) Real-time PCR
wasperformedonRNAsamples extracted fromH9c2 cells under different conditions. The expression levels of relatedmRNAswerenormalized to that ofGAPDH, thennormalized to the levels in
the control. Data are averages of at least three independent determinations. Error bars indicate standard deviations. Control values were ﬁxed at 1. ⁎Pb0.01 vs. control. (D) A schematic repre-
sentation showing that miR-350 induces pathological hypertrophy via SAPKs/NFAT-3 signaling pathways in myocardial cells. Stress provoked by TAC activates miR-350 expression, which re-
presses p38 and JNK genes involved in cardiac hypotrophy, apoptosis, and the myocardial gene program.miR-350 directly targets p38 and JNK1/2, which causes decreased phosphorylation of
NFATc3 and its nuclear translocation, resulting in the development of myocardial hypertrophy.
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In this study, our results have demonstrated that TAC in rats induces
a novel miRNA, miR-350. It is the only highly expressed miRNA identi-
ﬁed in the late stage of pressure overload-induced hypertrophy. Bioin-
formatics analysis revealed that miR-350 might interact with six key
components of the SAPK pathway. They are MAPKK3/7, MAPK11/14
(p38) andMARPK8/9 (JNK1/2), which all have seed sequences comple-
mentary to that of functional miR-350. Indeed, our data from Western
blotting and luciferase assays provide strong evidence that to control
the SAPK pathway with maximal efﬁciency, miR-350 may simulta-
neously inhibit MARPK8/9 and MAPK11/14. Moreover, gain- and loss-
of-function studies in cultured cardiomyocytes have demonstrated the
necessity and sufﬁciency of miR-350 alone to induce pathological CH,
suggesting that miR-350 functions as a key mediator of pathological
hypertrophy.
Expression ofmiRNAsmight be differentially regulated under differ-
ent conditions [33,34]. Recent studies have shown that some miRNAs
such as miR-23a, miR-27a, miR-24-2, miR-195 and miR-21 are up-
regulated in TAC-induced CH [18]. Their up-regulation may be neces-
sary for the induction [18] or suppression [35] of early-stage or adaptive
hypertrophy. However, our data indicated that miR-208 and miR-195
showed no notable alteration in late-stage CH, whereas miR-350 was
found to increase signiﬁcantly in response to late-stage TAC treatment
(Suppl. Table 1). It is reasonable to propose that miR-350 plays a critical
role in modulating the hypertrophic response and the succeeding tran-
sition towards heart failure caused by cell apoptosis. These studies sug-
gest that, in response to environmental perturbations at different
stages, cardiomyocytes alter the expression of miRNAs that participatein programs governing heart hypertrophic protein expression. These
changes in miRNA expression proﬁles can either promote or avert pro-
gressive ventricular dysfunction and heart failure.
Pathological hypertrophyoccurs in response to pathological stress sig-
nals. At themolecular level it is characterized by the activation of gene ex-
pression patterns associated with fetal development (Fig. 4C) [36,37].
Several studies have indicated that theMAPK signaling pathway is closely
associated with CH. The MAPK pathway is generally sub-classiﬁed into
three main branches consisting of p38 kinases, c-JunN-terminal kinases
(JNKs), and extracellular signal-regulated kinases (ERKs)[38]. Transgenic
mice over-expressing an activated MEK1 cDNA, which showed speciﬁc
activation of only ERK1/2, were characterized by a prominent hypertro-
phic response [39]. It has been shown that angiotensin II (Ang II) is a
major factor in the development of cardiomyocyte hypertrophy and a
pivotal role for Ang II signals via ERK1/2 and NFATc4 has been identiﬁed.
ERKs are particularly implicated in growth-associated responses [40]. Re-
cently, Ang II has been found to up-regulate the expression of miR-21 as-
sociated with CH [27]. However, miR-350 showed no changes following
stimulationwithAng II. In contrast, Ang II stimulated the phosphorylation
of JNK and p38 but did not lead to the nuclear translocation of NFATc3 in
cardiomyocytes (Figs. 2E and 4B). This suggests that the signaling path-
ways of miR-350 and Ang II are different. A combinatorial inhibition of
JNK and p38 is particularly responsible for pathological responses.
Information reported in the literature has not yet given a clear view
of the roles of speciﬁc MAPK pathways in CH. Rather, contradictory
results have led to a perception that MAPKs are ambiguous characters
in the heart, with both protective and detrimental effects [4,7,9,38].
Some studies have indicated that c-jun NH2-terminal kinases (JNKs)
and p38 kinases function as speciﬁc transducers of the stress response.
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pressure overload, while p38 activity is markedly induced in hearts
subjected to volume overload [41]. Moreover, MAPK signaling path-
ways have been shown to cooperate with calcineurin such that unitary
activation of calcineurin in myocytes leads to an up-regulation of ERK
and JNK signaling, but down-regulation of p38 signaling [4,38]. Con-
versely, unitary activation of JNK or p38 in cardiac myocytes leads to a
down-regulation in calcineurin effectiveness by directly antagonizing
NFAT nuclear occupancy [42]. It is likely that both stress-activated pro-
tein kinase-signaling branches have somewhat overlapping functions in
the heart aimed at counter-regulating cell behaviors such as apoptosis,
ﬁbrosis, survival, and growth. Considered together, these data imply
that distinct combined effects onmembers of theMAPK signaling path-
way, such that some are activated and some are inhibited, may be the
cause of the conﬂicting results found in previous studies.
Our studies have revealed that inhibition of both JNK and p38 path-
ways by miR-350 and its mimic could result in hypertrophy of
cardiomyocytes. This result is also consistent with the observation that
dominant negative JNK1/2 transgenicmice demonstrated enhanced car-
diac hypertrophic growth following pressure overload induced by aortic
banding [6]. Furthermore, transgenicmice expressing activatedMKK7 in
the heart showed speciﬁc JNK activation but not CH [29,43]. A similar
phenomenon was also observed with p38 signaling in the myocardium.
Cardiac-speciﬁc transgenic mice (dominant negative mutants of p38a,
MKK3, and MKK6) showed speciﬁc inhibition of p38 signaling that was
associated with spontaneous CH [3]. On the other hand, JNK and p38
are capable of directly phosphorylating speciﬁc NFAT transcription fac-
tors in their N-terminal regulatory domains, resulting in net inhibition
of nuclear occupancy [42]. For example, JNK factors can directly phos-
phorylate NFATc1, NFATc2 and NFATc3, but not NFATc4. By comparison,
p38 was shown to phosphorylate NFATc1, NFATc2 and NFATc4 directly,
but not NFATc3 [44,45]. Thus, suppressing the expression of both JNK
andp38 bymiR-350may cause dephosphorylation of all theNFATmem-
bers and their translocation to the nucleus, implying that miR-350 can
induce CH in a more effective manner.
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